PROCEPT BioRobotics Launches HYDROS Robotic System in the UK: Revolutionizing BPH Treatment with AI-Enabled Aquablation Therapy
PROCEPT BioRobotics has launched its HYDROS Robotic System in the United Kingdom, with plans for further international expansion in 2026. The system is designed to provide Aquablation therapy for treating benign prostatic hyperplasia (BPH) using AI-interpreted ultrasound imaging and treatment planning. Clinical evidence shows that Aquablation therapy offers symptom relief while preserving sexual and urinary function for men with BPH. The company aims to address the needs of the estimated 40 million men in the United States affected by BPH.
Despite facing challenges, PROCEPT BioRobotics has experienced strong revenue growth of 37% over the past year, reaching $308 million. The company's stock has surged by 9.66% in the last week, reflecting investor confidence in its innovative robotic solutions. The HYDROS Robotic System expands access to advanced AI-enabled treatment options, providing durable symptom relief and improving quality of life for patients.
The international launch of the HYDROS Robotic System marks a significant milestone for PROCEPT BioRobotics, as it brings cutting-edge technology to the UK for Aquablation therapy. The system's real-time ultrasound guidance and robotic-assisted treatment planning enhance the precision and effectiveness of the procedure, aligning with NICE recommendations for BPH treatment. The company's commitment to clinical validation and evidence-based practice underscores its dedication to improving patient outcomes.
In response to recent financial results, analysts have adjusted their price targets for PROCEPT BioRobotics, reflecting varying perspectives on the company's performance and future prospects. Despite revisions in guidance, the company's strategic commercial changes and focus on innovation continue to drive confidence among investors and industry experts. The appointment of new board members, including independent director Daniel Puckett, further strengthens the company's governance and oversight, positioning it for future growth and success.
PROCEPT BioRobotics remains at the forefront of robotic-assisted medical technology, with a strong emphasis on clinical validation and evidence-based practice. The company's commitment to advancing treatment options for BPH and other urological conditions underscores its dedication to improving patient care and outcomes. As the HYDROS Robotic System expands internationally, PROCEPT BioRobotics is poised to make a significant impact on the field of urology, offering innovative solutions that enhance surgical precision and patient outcomes.